ClinicalTrials.gg
RecruitingNCT07341854Updated Aug 19, 2026

Dexamethasone Palmitate for Postoperative Pain

An interventional study of dexamethasone palmitate and Dexamethasone in Pain, Postoperative and Dexamethasone Palmitate, sponsored by Beijing Tiantan Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-08-19.

Sponsored by Beijing Tiantan Hospital · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Apr 2026; still recruiting 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
446
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 28 studies in Pain, Postoperative by Beijing Tiantan Hospital — 8 open to participants now, 9 under way, 1 of them phase 3. Pain, Postoperative · Beijing Tiantan Hospital.

Planned enrollment
3rd of 28
446 · median 136
Started
2026
with 5 others
No phase
11 of 28
6 open now
Registered
24th of 28
by date

Among the 28 studies in Pain, Postoperative by Beijing Tiantan Hospital, this one is the 3rd largest by planned enrollment, is one of 6 that started in 2026, is one of 11 with no phase, and was the 24th registered.

Pain, Postoperative

5,680 studies on the registry are indexed under Pain, Postoperative; 1,243 are open to participants now.

Browse Pain, Postoperative studies →

Open to participants now

8 of the 28 studies in Pain, Postoperative by Beijing Tiantan Hospital are open now, in 1 country. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Where they have run

Who these studies take

Of the 678 Pain, Postoperative studies recruiting now, 239 (35%) set no upper age limit and 329 (49%) stop at 75 or younger; 74 take children under 18; 129 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies in Pain, Postoperative by Beijing Tiantan Hospital, or all of them as a file.
02

Study summary

Postoperative pain remains highly prevalent and inadequately managed in a significant proportion of surgical patients, often leading to delayed recovery, increased opioid consumption, and potential progression to chronic pain. While perioperative systemic dexamethasone is used for its anti-inflammatory and opioid-sparing effects, its efficacy is inconsistent, and concerns regarding systemic side effects persist. Dexamethasone palmitate, a novel lipophilic prodrug formulated as nanoparticle emulsion, leverages the enhanced permeability and retention effect to target inflammatory sites selectively, potentially offering superior anti-inflammatory and analgesic efficacy with reduced systemic exposure. This trial aims to evaluate whether preoperative intravenous dexamethasone palmitate is more effective than conventional dexamethasone in preventing moderate-to-severe postoperative pain.

03

Conditions studied

  • Pain, Postoperative
  • Dexamethasone Palmitate

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 18-65 years.
  2. Scheduled for a range of surgeries under general anesthesia, including both minimally invasive procedures (such as video-assisted thoracoscopic surgery and laparoscopy) and open surgeries (such as thoracotomy, laparotomy, spinal surgery, total joint replacement, and mastectomy).
  3. Capacity to comprehend the study procedures and assessment scales, and communicate effectively with research staff.

4)Classified as (ASA) physical status I, II, or III.

5) Willingness to participate voluntarily and provide written .

Exclusion criteria

Exclusion Criteria:

  1. Known to dexamethasone or its .
  2. Systemic therapy within 3 months prior to enrolment.
  3. History of severe cardiovascular disease, hepatic or renal failure, or systemic rheumatic disease (e.g., rheumatoid arthritis, ankylosing spondylitis, systemic lupus erythematosus).
  4. Coexisting chronic pain at enrolment.
  5. Uncontrolled diabetes mellitus or active systemic infection.
  6. Use of any systemic or topical analgesics within 48 hours prior to surgery.
  7. Significant cognitive impairment or severe psychiatric disorder.
  8. Pregnancy or lactation.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
446 participants (estimated)

Study arms

  • Experimental
    Dexamethasone palmitate group

    Patients assigned to the dexamethasone palmitate group will receive an intravenous injection of 8 mg dexamethasone palmitate after induction of anaesthesia but prior to surgical incision.

    Drug: dexamethasone palmitate

  • Active comparator
    Dexamethasone group

    Patients in the dexamethasone group will receive an intravenous injection of 8 mg dexamethasone after induction of anaesthesia but prior to surgical incision.

    Drug: Dexamethasone

Interventions

  • Patients assigned to the dexamethasone palmitate group will receive an intravenous injection of 8 mg dexamethasone palmitate after induction of anaesthesia but prior to surgical incision.

  • Patients in the dexamethasone group will receive an intravenous injection of 8 mg dexamethasone after induction of anaesthesia but prior to surgical incision.

06

What researchers measure

Primary outcomes

  1. The percentage of participants experiencing moderate to severe pain

    The percentage of participants experiencing moderate to severe pain (Visual Analog Scale \[VAS\]\>30 mm)

    Time frame: 24 hours after surgery

Secondary outcomes

  1. Cumulative opioid consumption

    Cumulative opioid consumption, expressed as morphine milligram equivalents (MME)

    Time frame: At 6, 24, 48, and 72 hours postoperatively

  2. The total consumption of supplemental oxycodone/paracetamol tablets

    The total consumption of supplemental oxycodone/paracetamol tablets, expressed as the number of tablets

    Time frame: At 6, 24, 48, and 72 hours postoperatively

  3. The proportion of participants experiencing moderate to severe pain

    The proportion of participants experiencing moderate to severe pain at rest and during passive movement (e.g., coughing, deep breathing, or following a 5 m walk test)

    Time frame: At 6, 24, 48, and 72 hours postoperatively

  4. Time to first patient-controlled analgesia (PCA) bolus request

    Time to first PCA bolus request

    Time frame: Within the first 72 hours postoperatively

  5. Participant satisfaction with pain management

    Using a 0-10 point numerical rating scale (NRS) (0 = very dissatisfied to 10 = most satisfied imaginable)

    Time frame: At 6, 24, 48, and 72 hours postoperatively and at discharge

  6. Incidences of postoperative nausea and vomiting (PONV)

    PONV is defined as any nausea, vomiting, retching, or combination thereof. Nausea refers to an unpleasant sensation associated with the urge to vomit; vomiting is defined as the forceful expulsion of gastric contents; and retching indicates an involuntary attempt to vomit without producing gastric contents.

    Time frame: At 6, 24, 48, and 72 hours after surgery

  7. Quality of recovery

    Quality of recovery will be measured using the 15-item quality of recovery scoring system \[QoR-15\] questionnaire. The total score ranges from 0 to 150, where higher scores indicate a better quality of recovery.

    Time frame: At 24, 48, and 72 hours postoperatively, as well as at 1 month after surgery.

  8. Length of hospital stay

    Length of hospital stay was defined as the number of days from the date of hospital admission to the date of discharge.

    Time frame: From the date of hospital admission to the date of discharge, assessed throughout the hospitalization period (up to 1 month).

  9. Incidence of postoperative adverse events

    This outcome measure assesses the occurrence of specified safety events within six month after surgery. The number of participants experiencing any of the following confirmed events will be recorded and reported based on clinical examination, medical record review, and necessary laboratory tests: hypotension, hypertension, gastrointestinal ulcers, poor wound healing, surgical site infection, urinary retention, and hyperglycemia. Data will be aggregated and reported as event frequency and participant count.

    Time frame: Within six month after surgery

  10. Pain intensity

    (0 = no pain, 100mm = worst imaginable pain)

    Time frame: upon arrival in the PACU after the patient becomes conscious (0 hour), and at 6, 24, 48, and 72 hours postoperatively, as well as at discharge, and at 1 month, 3 month, and 6 month follow up.

  11. total PCA attempts

    Participant' total PCA attempts patients' total PCA attempts patients' total PCA attempts

    Time frame: Within the first 72 hours postoperatively

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Gan TJ, Habib AS, Miller TE, White W, Apfelbaum JL. Incidence, patient satisfaction, and perceptions of post-surgical pain: results from a US national survey. Curr Med Res Opin. 2014 Jan;30(1):149-60. doi: 10.1185/03007995.2013.860019. Epub 2013 Nov 15. PubMed 24237004 ↗
  • Apfelbaum JL, Chen C, Mehta SS, Gan TJ. Postoperative pain experience: results from a national survey suggest postoperative pain continues to be undermanaged. Anesth Analg. 2003 Aug;97(2):534-540. doi: 10.1213/01.ANE.0000068822.10113.9E. PubMed 12873949 ↗
  • Liu Y, Xiao S, Yang H, Lv X, Hou A, Ma Y, Jiang Y, Duan C, Mi W; CAPOPS Group. Postoperative pain-related outcomes and perioperative pain management in China: a population-based study. Lancet Reg Health West Pac. 2023 Jun 10;39:100822. doi: 10.1016/j.lanwpc.2023.100822. eCollection 2023 Oct. PubMed 37927993 ↗
  • Gandhi K, Heitz JW, Viscusi ER. Challenges in acute pain management. Anesthesiol Clin. 2011 Jun;29(2):291-309. doi: 10.1016/j.anclin.2011.04.009. PubMed 21620344 ↗
  • Gan TJ. Poorly controlled postoperative pain: prevalence, consequences, and prevention. J Pain Res. 2017 Sep 25;10:2287-2298. doi: 10.2147/JPR.S144066. eCollection 2017. PubMed 29026331 ↗
  • Tammachote N, Kanitnate S. Intravenous Dexamethasone Injection Reduces Pain From 12 to 21 Hours After Total Knee Arthroplasty: A Double-Blind, Randomized, Placebo-Controlled Trial. J Arthroplasty. 2020 Feb;35(2):394-400. doi: 10.1016/j.arth.2019.09.002. Epub 2019 Sep 7. PubMed 31587982 ↗
  • Kitcharanant N, Leurcharusmee P, Atthakomol P, Jingjit W. Perioperative intravenous dexamethasone did not reduce the severity of persistent postsurgical pain after total knee arthroplasty: a prospective, randomized, double-blind, placebo-controlled trial. J Orthop Surg Res. 2024 Dec 19;19(1):854. doi: 10.1186/s13018-024-05362-y. PubMed 39702151 ↗
  • Lorscheider M, Tsapis N, Ur-Rehman M, Gaudin F, Stolfa I, Abreu S, Mura S, Chaminade P, Espeli M, Fattal E. Dexamethasone palmitate nanoparticles: An efficient treatment for rheumatoid arthritis. J Control Release. 2019 Feb 28;296:179-189. doi: 10.1016/j.jconrel.2019.01.015. Epub 2019 Jan 16. PubMed 30659904 ↗
  • Hui H, Miao H, Qiu F, Lin Y, Li H, Zhang Y, Jiang B. Adjunctive dexamethasone palmitate use for intercostal nerve block after video-assisted thoracoscopic surgery: A prospective, randomized control trial. Heliyon. 2023 Aug 22;9(9):e19156. doi: 10.1016/j.heliyon.2023.e19156. eCollection 2023 Sep. PubMed 37662806 ↗

Individual participant data

Plan to share: Yes — All personal identifiers will be stored securely by the principal investigator, separate from the pseudonymized study data. Access is restricted to the research team, and all published findings will be based on anonymized data aggregates.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Jun 2027, 14 months after the start.

Of 2,113 non-industry interventional studies with no phase under Pain, Postoperative, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 23. This study's planned 14 months is above that.

Counting every sponsor, half of 2,126 studies reached it within 11 months; a quarter within 6 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 14, 2025
First posted
Jan 14, 2026
StartActual
Apr 6, 2026
Primary completionEst.
Jun 30, 2027
CompletionEst.
Dec 30, 2027
Last update
Aug 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 19, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07341854
Collaborators
Beijing Ditan Hospital, Beijing Electric Power Hospital, Beijing Sanbo Brain Hospital
Responsible party
Fang Luo (Director of Department of Pain Management, Beijing Tiantan Hospital) — Principal investigator
First posted
Jan 14, 2026
Start date
Apr 6, 2026
Primary completion
Jun 30, 2027 (estimated)
Completion
Dec 30, 2027 (estimated)
Last update
Aug 19, 2026

Study contacts

Fang Luo
Contact
13611326978@163.com
59976661

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dexamethasone palmitate

Start the discussion